Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence
Seasonal influenza is a very common disease. Yearly vaccination of at-risk population groups is a well-recognized cost-effective/cost-saving preventive measure. It is, however, unclear which available alternative has the most favorable economic profile. Some available options are: trivalent (TIV) an...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Taylor & Francis Group
2019-05-01
|
| Edice: | Human Vaccines & Immunotherapeutics |
| Témata: | |
| On-line přístup: | http://dx.doi.org/10.1080/21645515.2019.1578597 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|